Prostate-specific antigen-based prostate cancer screening: Past and future (Q38408501)

2 September 2017

1 reference

title

Prostate-specific antigen-based prostate cancer screening: Past and future (English)

1 reference

prostate cancer screening

2 September 2017

main subject

1 reference

1 reference

Arnout R Alberts

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25847604 AND SRC:MED&resulttype=core&format=json

8 June 2020

publication date

6 April 2015

1 reference

International Journal of Urology

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25847604 AND SRC:MED&resulttype=core&format=json

8 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25847604 AND SRC:MED&resulttype=core&format=json

8 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25847604 AND SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

524-532

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25847604 AND SRC:MED&resulttype=core&format=json

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

8 June 2020

cites work

1 reference

Prostate cancer in Asian men.

21 January 2018

1 reference

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.

21 January 2018

1 reference

Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer

21 January 2018

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

21 January 2018

1 reference

Randomised prostate cancer screening trial: 20 year follow-up

21 January 2018

1 reference

15-year followup of a population based prostate cancer screening study

21 January 2018

1 reference

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.

21 January 2018

1 reference

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

21 January 2018

1 reference

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

21 January 2018

1 reference

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

21 January 2018

1 reference

Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer

21 January 2018

1 reference

Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden

21 January 2018

1 reference

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

21 January 2018

1 reference

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

Prostate-cancer mortality at 11 years of follow-up

21 January 2018

1 reference

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

21 January 2018

1 reference

Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening

21 January 2018

1 reference

Quality-of-life effects of prostate-specific antigen screening.

21 January 2018

1 reference

Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

21 January 2018

1 reference

ERSPC and PLCO prostate cancer screening studies: what are the differences?

21 January 2018

1 reference

The impact of PLCO control arm contamination on perceived PSA screening efficacy

21 January 2018

1 reference

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines

21 January 2018

1 reference

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

Screening for prostate cancer: an updated Cochrane systematic review

21 January 2018

1 reference

Screening for prostate cancer

21 January 2018

1 reference

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program

21 January 2018

1 reference

Infectious complications and hospital admissions after prostate biopsy in a European randomized trial

21 January 2018

1 reference

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.

21 January 2018

1 reference

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

21 January 2018

1 reference

Overdiagnosis and overtreatment of prostate cancer

21 January 2018

1 reference

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms

21 January 2018

1 reference

Screening for prostate cancer in the US? Reduce the harms and keep the benefit.

21 January 2018

1 reference

21 January 2018

1 reference

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

International perspectives on screening.

21 January 2018

1 reference

Early detection of prostate cancer: AUA Guideline

21 January 2018

1 reference

Early detection of prostate cancer: European Association of Urology recommendation

21 January 2018

1 reference

Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians

21 January 2018

1 reference

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

21 January 2018

1 reference

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion

21 January 2018

1 reference

American Cancer Society guideline for the early detection of prostate cancer: update 2010

21 January 2018

1 reference

Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.

21 January 2018

1 reference

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice

21 January 2018

1 reference

The Melbourne Consensus Statement on the early detection of prostate cancer

21 January 2018

1 reference

Beyond PSA: the next generation of prostate cancer biomarkers

21 January 2018

1 reference

DNA-based detection of prostate cancer in urine after prostatic massage

21 January 2018

1 reference

The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer

21 January 2018

1 reference

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

21 January 2018

1 reference

Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.

21 January 2018

1 reference

Repeat prostate biopsy: who, how and when?. a review

21 January 2018

1 reference

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

21 January 2018

1 reference

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

21 January 2018

1 reference

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study

21 January 2018

1 reference

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

21 January 2018

1 reference

[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study

21 January 2018

1 reference

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting

21 January 2018

1 reference

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France

21 January 2018

1 reference

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication

21 January 2018

1 reference

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening

21 January 2018

1 reference

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators

21 January 2018

1 reference

Risk-based prostate cancer screening.

21 January 2018

1 reference

A graphical device to represent the outcomes of a logistic regression analysis.

21 January 2018

1 reference

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

21 January 2018

1 reference

Compliance with biopsy recommendations of a prostate cancer risk calculator.

21 January 2018

1 reference

Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

21 January 2018

1 reference

Prediction of prostate cancer in unscreened men: external validation of a risk calculator

21 January 2018

1 reference

Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.

21 January 2018

1 reference

Improved prostate cancer detection with anterior apical prostate biopsies

21 January 2018

1 reference

Importance of additional "extreme" anterior apical needle biopsies in the initial detection of prostate cancer

21 January 2018

1 reference

Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients

21 January 2018

1 reference

Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study

21 January 2018

1 reference

Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients

21 January 2018

1 reference

Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging

21 January 2018

1 reference

Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance

21 January 2018

1 reference

Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen

21 January 2018

1 reference

Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study

21 January 2018

1 reference

Screening and detection advances in magnetic resonance image-guided prostate biopsy

21 January 2018

1 reference

A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion

21 January 2018

1 reference

Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies

21 January 2018

1 reference

Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review

21 January 2018

1 reference

Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.

21 January 2018

1 reference

Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound–Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies

21 January 2018

1 reference

Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.

21 January 2018

1 reference

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

21 January 2018

1 reference

ESUR prostate MR guidelines 2012

21 January 2018

1 reference

Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group

21 January 2018

1 reference

Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort

21 January 2018

1 reference